Oxford Bio Announces Launch of Enhanced Discovery Platform, OGAP®-Verify
OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors Oxford, UK,...
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 antigen was discovered using OBT™s proprietary OGAP® drug discovery...
BI 764532 was discovered using OBT™s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets ...
Oxford, UK and San Jose, Calif., 11 October 2023 Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 proteinDLL3 was discovered using OBT™s proprietary OGAP® drug discovery platformFast...
Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe OBT initiates...
Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said that the extension will add more programs to allow for developing “novel cancer immunotherapies” in indications with a higher unmet need.
Oxford, UK and San Jose, Calif., 25 May 2023 Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck